Search

Your search keyword '"Mitsushita, Junji"' showing total 27 results
Start Over Author "Mitsushita, Junji"
27 results on '"Mitsushita, Junji"'

2. Supplementary Table, Figures 1-4 from NADPH Oxidase 4 Contributes to Transformation Phenotype of Melanoma Cells by Regulating G2-M Cell Cycle Progression

Author

Yamaura, Maki, primary, Mitsushita, Junji, primary, Furuta, Shuichi, primary, Kiniwa, Yukiko, primary, Ashida, Atsuko, primary, Goto, Yasuhumi, primary, Shang, Wei H., primary, Kubodera, Makoto, primary, Kato, Masayoshi, primary, Takata, Minoru, primary, Saida, Toshiaki, primary, and Kamata, Tohru, primary

Published
2023
Full Text
View/download PDF

4. EUS-FNA で診断された膵 insulinoma の 1 例

Author

MITSUSHITA, Junji, primary, TANAKA, Yuko, additional, SUZUKI, Aya, additional, MATSUMOTO, Yumiko, additional, HAYASHI, Yosuke, additional, IIZUKA, Mika, additional, SHIRAKURA, Isuzu, additional, KANEKO, Tsukasa, additional, and OGAWA, Akira, additional

Published
2023
Full Text
View/download PDF

11. A case of borderline Brenner tumor of the ovary

Author

MITSUSHITA, Junji, primary, OKAMOTO, Sanshiro, additional, KOMATSU, Kyoko, additional, FURUTA, Noriyuki, additional, TAKESHIMA, Nobuhiro, additional, SUGIYAMA, Yuko, additional, TAKEUCHI, Kengo, additional, and TAKAZAWA, Yutaka, additional

Published
2021
Full Text
View/download PDF

18. NADPH Oxidase 4 Contributes to Transformation Phenotype of Melanoma Cells by Regulating G2-M Cell Cycle Progression

Author

Yamaura, Maki, primary, Mitsushita, Junji, additional, Furuta, Shuichi, additional, Kiniwa, Yukiko, additional, Ashida, Atsuko, additional, Goto, Yasuhumi, additional, Shang, Wei H., additional, Kubodera, Makoto, additional, Kato, Masayoshi, additional, Takata, Minoru, additional, Saida, Toshiaki, additional, and Kamata, Tohru, additional

Published
2009
Full Text
View/download PDF

26. Enhancement of antitumor effect of bleomycin by low-voltage <TOGGLE>in vivo</TOGGLE> electroporation: A study of human uterine leiomyosarcomas in nude mice

Author

Horiuchi, Akiko, Nikaido, Toshio, Mitsushita, Junji, Toki, Toshihiko, Konishi, Ikuo, and Fujii, Shingo

Abstract

Uterine leiomyosarcoma is an extremely malignant neoplasm with high rates of distant metastasis, and systemic chemotherapy is not particularly effective. Thus, the introduction of more active anticancer agents, or of a new drug delivery system, is urgently needed. Recently, electrochemotherapy has been introduced as a way of enhancing the cytotoxic effects of chemotherapeutic agents. This involves administering the drug in combination with electric pulses (which permeabilize tumor cell membranes and allow the drug to enter the cells). In particular, bleomycin (BLM) cannot cross the plasma membrane efficiently, but its cytotoxicity can be enhanced by electropermeabilization. The aim of the present study was to investigate the effect of low-voltage electroporation (EP) in combination with local BLM injection on the growth of uterine leiomyosarcoma in nude mice. Human uterine leiomyosarcoma cells (SK-LMS-1) were implanted subcutaneously into nude mice. Tumor growth in mice treated with EP (100 V/cm) plus BLM was compared with that in mice receiving BLM alone, EP alone, or no treatment (controls). Tissue BLM concentrations and histological analysis (including mitotic counts) were evaluated in tumor tissues. There was a significant reduction in tumor growth in mice that received EP with BLM. One hour after the treatment, the local BLM concentration was 10 times higher in the tumors that received EP with BLM than in those receiving only BLM. Moreover, the mitotic count was lower in the tumors that received EP plus BLM than in the controls. These results demonstrate the possible therapeutic value of low-voltage EP with BLM in human uterine leiomyosarcoma. Int. J. Cancer 88:640–644, 2000. © 2000 Wiley-Liss, Inc.

Published
2000
Full Text
View/download PDF

27. [Human papillomavirus vaccination for prevention of cervical cancer].

Author

Hayashi Y, Mitsushita J, Netsu S, and Konno R

Subjects
Adolescent, Female, Humans, Vaccination, Papillomavirus Vaccines, Uterine Cervical Neoplasms prevention & control
Abstract

Persistent infection of human papillomavirus (HPV) is the necessary cause for developing cervical cancer. Now cervical cancer is getting attention as not only early-detectable but also preventable cancer by developing vaccine for HPV. In Japan, the first HPV vaccine, "Cervarix, GlaxoSmithKline (GSK)" was licensed on October 2009 and vaccination was started on December 2009. This is the bivalent vaccine specifically targeting HPV-16 and -18 types. Domestic clinical trial is also about to demonstrate the efficacy, safety, and possibility to keep enough antibody levels. The widespread use of this vaccine will help cervical cancer eliminated.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results